Chester County News and Community Website
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in the DUBSTENT DIABETES trial, a new clinical study designed to evaluate whether combining two …
Teleflex Launches Clinical Trial Testing Dual-Device Heart Procedure for Diabetic Patients Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced new subgroup analyses from its Phase 3 Launch-HTN trial, showing that its investigational therapy lorundrostat significantly lowered blood pressure across multiple …
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) released new data at the HRX Live 2025 Meeting in Atlanta showing that its atrioventricular interval modulation (AVIM) therapy produces …
Orchestra BioMed Reports Long-Term Data Supporting AVIM Therapy for Hypertension Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that the results of its Phase 3 IMPALA-2 clinical trial for molgramostim, an inhaled therapy for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), …
Savara’s Phase 3 Trial Shows Promising Results for Rare Lung Disease Treatment Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced it has received approval from the Human Research Ethics Committee (HREC) to begin Phase 2 clinical trials of ratutrelvir, a ritonavir-free …
Traws Pharma Receives Approval to Launch Phase 2 Trials for Ritonavir-Free COVID Treatment Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported new peer-reviewed findings demonstrating that its investigational DNA immunotherapy, INO-3107, continues to deliver long-term clinical benefits for patients with recurrent respiratory papillomatosis …
INOVIO’s INO-3107 Shows Sustained Long-Term Benefits for Patients With Recurrent Respiratory Papillomatosis Read More RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported a series of positive clinical milestones and second-quarter 2025 financial results, positioning its lead drug candidate, lorundrostat, for a potential new …
Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported progress on its pivotal Phase 3 trial in early Alzheimer’s disease while posting improved second-quarter financial results and expanding its intellectual …
Annovis Bio Advances Alzheimer’s Phase 3 Trial, Strengthens IP Portfolio Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported encouraging early clinical results from its two lead oncology programs while narrowing its quarterly loss, according to second-quarter 2025 financial results …
Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026 Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in its upliFT-D clinical trial, including completion of dosing in the second cohort of …
Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027 Read More